1. Progression-free survival was significantly higher in the talazoparib plus enzalutamide group compared to enzalutamide alone. 2. There were no treatment-related fatalities among patients in the talazoparib group. Evidence Rating Level: 1 (Excellent) Study Rundown: Prostate cancer is the second most common malignancy among men. Despite existing therapies, metastatic castration-resistant prostate cancer (mCRPC) remains a
Neeraj Agarwal, MD, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC.